Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Lisa Borbridge"'
Publikováno v:
Clinical Pharmacology in Drug Development.
Autor:
Matthew Butler, Danielle McGeeney, Antonia Periclou, Li Yao, Brian McNamee, Lisa Borbridge, Ramesh Boinpally
Publikováno v:
Clinical Pharmacology in Drug Development
Atogepant is a selective, oral calcitonin gene–related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double‐blind, phase 1 crossover study evaluated the cardiac repolarization effect of a single
Autor:
Andrew M. Blumenfeld, Lisa Borbridge, Janette Contreras-De Lama, Abhijeet Jakate, Ramesh Boinpally, Antonia Periclou, Matthew Butler, Richard B. Lipton, Danielle McGeeney
Publikováno v:
Headache
Objective To evaluate the impact of two calcitonin gene–related peptide (CGRP)‐targeted monoclonal antibodies (mAbs), erenumab and galcanezumab, on the pharmacokinetic (PK) profile, safety, and tolerability of ubrogepant. Background People taking
Publikováno v:
Clinical Pharmacology in Drug Development
Atogepant is a selective oral calcitonin gene‐related peptide receptor antagonist in development for migraine prevention. Here, we report the pharmacokinetics (PK) and safety of single‐dose 60 mg atogepant in participants with severe, moderate, o
Autor:
Andrew Acheampong, Devin F. Welty, Carmai Seto, Jinsong Ni, Takeo Sakuma, Lisa Borbridge, Robert Ellis, Mauro Aiello, Hui Ouyang
Publikováno v:
Pharmaceutical Research. 25:1572-1582
To evaluate the sensitivity requirement for LC-MS/MS as an analytical tool to support human microdosing study with sub-pharmacological dose, investigate proportionality of pharmacokinetics from the microdose to therapeutic human equivalent doses in r
Autor:
David A Hollander, Rhett M. Schiffman, Linda Villanueva, Milan Patel, Lisa Borbridge, L. David Waterbury, Mayssa Attar, Danielle Galindo, Cathy Nguyen
Anti-inflammatory activity of topical nonsteroidal anti-inflammatory drugs is mediated by suppression of cyclooxygenase (COX) isoenzymes. This study compared ocular penetration and inflammation suppression of topical ketorolac 0.45% and bromfenac 0.0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fb704b3b248c7d5d4f6fba6107d44be
https://europepmc.org/articles/PMC3078535/
https://europepmc.org/articles/PMC3078535/
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Mayssa Attar1, Rhett Schiffman2, Lisa Borbridge3, Quinn Farnes4, Devin Welty11Departments of Pharmacokinetics and Drug Metabolism, 2Global Production Enhancement, 3Bioanalytical Sciences, 4Product Formulation Development, Allergan Inc., Irvine, CA, U
Autor:
Jinsong Ni, Hui Ouyang, Mauro Aiello, Carmai Seto, Lisa Borbridge, Takeo Sakuma, Robert Ellis, Devin Welty, Andrew Acheampong
Publikováno v:
Pharmaceutical Research; Jul2008, Vol. 25 Issue 7, p1572-1582, 11p